• Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • What Controls Liver Size?

What Controls Liver Size?

Most people know that liver can regenerate, but how does it know when to stop growing? Liver size is, in part, regulated by the size of the circulating bile acid pool, controlled by fibroblast growth factor 19 (FGF19), researchers show in the September issue of Gastroenterology. The mammalian liver can

Read more